LENZ Therapeutics, Inc. (LENZ) Year-over-year earnings per share growth for the last twelve months

lenz-tx.com - graphic logo of issuer LENZ

LENZ Therapeutics, Inc. (LENZ) plans to generate revenue by launching innovative drops to treat presbyopia. A shortage of effective alternatives will provide the company with significant pricing power following certification. On GURU.Markets, quarterly earnings per share (EPS) growth illustrates the yield dynamics, where -68.00 serves as the current parameter value. Patent protection for the drug's unique formulation ensures the company's position remains resilient against potential generics.

lenz-tx.com (LENZ) Year-over-year earnings per share growth for the last twelve months: for the period 03/23/2024 - 11/17/2026

Comprehensive metric breakdowns and analytics for LENZ Therapeutics (LENZ)

- share price and expert price forecast:
General company analysis:LENZ Pharma, LENZ
Manufactured product of lenz-tx.com

LENZ Therapeutics, Inc. (LENZ) focuses on developing innovative presbyopia drops amid stringent regulatory pressure. The quarterly EPS growth vector reflects the dynamics of expected net income per share, integrating market forecasts for future periods. This metric measures the rate of change in profitability, allowing investors to assess the business's operational momentum. Current commercial launch costs and competition directly drive the volatility of this curve. Analyzing this indicator helps prevent overpaying for the asset.

Who LENZ Therapeutics, Inc. competes with

Alcon Corp (ALC) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Bausch Health (BLCO)|Year-over-year earnings per share growth for the last twelve months glaukos.com|Apellis Pharmaceuticals (APLS) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth BLTE|OCUL - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth HROW (Harrow Inc)|Year-over-year net earnings per share change for the last twelve months Viridian Corp (VRDN)|OCS: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months eyepointpharma.com|KOD: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aldeyra Therapeutics (ALDX)|Year-over-year net earnings per share growth for the last 12 months KALA|IRD - Net earnings per share growth for the trailing year|Year-over-year earnings per share growth for the last twelve months okyopharma.com (OKYO)|Quarterly EPS earnings growth Adverum Biotechnologies Inc. (ADVM)|Year-over-year earnings per share growth for the last twelve months outlooktherapeutics.com OTLK|Year-over-year net earnings per share change for the last twelve months Clearside Biomedical, Inc. (CLSD)|NBY - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months KPRX (kiorapharma.com)|Alimera Sciences (ALIM) - Year-over-year earnings per share growth for the last twelve months|Eyenovia Inc. - Year-over-year earnings per one share growth for the last 12 months|GHSI (Guardion Health Sciences) - Quarterly EPS earnings growth|Ocuphire Pharma - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OPT (Opthea)